Cargando…

Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials

BACKGROUND: Zoledronic acid (ZOL) is an important component of therapy for patients with metastatic bone disease (MBD) to reduce the risk of skeletal-related events (SREs). We evaluated overall survival (OS) in patients with MBD secondary to solid tumours included in placebocontrolled ZOL trials. PA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coleman, Robert E., Lipton, Allan, Costa, Luis, Cook, Richard J., Lee, Ker-Ai, Saad, Fred, Brown, Janet E., Terpos, Evangelos, Major, Pierre P., Kohno, Norio, Smith, Matthew, Body, Jean-Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723367/ https://www.ncbi.nlm.nih.gov/pubmed/26909273 http://dx.doi.org/10.1016/j.jbo.2013.01.002

Ejemplares similares

Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity
por: Major, Pierre P, et al.
Publicado: (2009)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Zoledronic acid plus methylprednisolone versus zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial
por: Cai, Guoqi, et al.
Publicado: (2019)

Gorham–Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid
por: Yerganyan, V.V., et al.
Publicado: (2015)

The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
por: Hadji, Peyman, et al.
Publicado: (2012)

Stathmin is involved in the cooperative effect of Zoledronic acid and gefitinib on bone homing breast cancer cells in vitro
por: Oda, Miki, et al.
Publicado: (2012)

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
por: Coleman, R E, et al.
Publicado: (2010)

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
por: Raje, N, et al.
Publicado: (2016)

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
por: Steinman, Richard A, et al.
Publicado: (2012)

High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases
por: Quiñones Vélez, Gabriel, et al.
Publicado: (2022)

A case of contralateral inguinal lymph node metastases from breast cancer
por: Kimoto, Takeo, et al.
Publicado: (2021)

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
por: Kroep, J.R., et al.
Publicado: (2015)

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2007)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers
por: Choi, Jinhyun, et al.
Publicado: (2019)

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
por: Nakamura, T., et al.
Publicado: (2016)

Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases
por: Quattrocchi, Carlo C., et al.
Publicado: (2012)

Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases
por: Wang, Gengshen, et al.
Publicado: (2018)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
por: Jagdev, S P, et al.
Publicado: (2001)

Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid
por: Lefley, DV, et al.
Publicado: (2008)

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
por: Hadji, P., et al.
Publicado: (2012)

The clinical course of bone metastases from breast cancer.
por: Coleman, R. E., et al.
Publicado: (1987)

The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells
por: Brown, Hannah K, et al.
Publicado: (2011)

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
por: Body, Jean-Jacques, et al.
Publicado: (2017)

The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway
por: Wilson, Caroline, et al.
Publicado: (2015)

Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
por: Tokumaru, Yoshihisa, et al.
Publicado: (2019)

CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases
por: Petruk, Nataliia, et al.
Publicado: (2023)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Zoledronate rescues immunosuppressed monocytes in sepsis patients
por: Raffray, Loïc, et al.
Publicado: (2019)

The effect of zoledronic acid on hip geometry in renal transplant recipients: a double-blind placebo-controlled randomized study
por: Dabbaghmanesh, Alireza, et al.
Publicado: (2023)

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid
por: Zhao, Xinmin, et al.
Publicado: (2011)

RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study
por: Mercatali, Laura, et al.
Publicado: (2013)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Codelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles
por: Chen, Li, et al.
Publicado: (2013)

Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
por: Møller, Anaïs M J, et al.
Publicado: (2020)

Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study
por: von Moos, Roger, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6uk8b02ldi51l95em0ftumvoit